Monday, April 20, 2015

Two New Ebola Vaccines Pass Important Early Test, Researchers Say

News Brief by Samantha Fine

Researchers confirmed that two new Ebola vaccines have been proven to protect monkeys from the strain of the deadly virus without any side effects. However, the vaccines have not been tested on humans yet. Older vaccines have traditionally caused side effects such as fever and joint and muscle pain. Thomas W. Geisbert, an Ebola expert at the University of Texas in Galveston, stated that human trials of the new vaccines will begin in the summer. These recent vaccines were made by the company Profectus BioSciences, which received $55 million to conduct research on Ebola vaccines. The vaccines are made from the vesicular stomatitis virus (V.S.V), which causes an oral disease in cattle but rarely infects humans. In the Ebola vaccines, V.S.V is engineered to make a protein from the surface of the Ebola virus; this protein communicates with the immune system and assists it in recognizing and fighting off the Ebola infection. Future studies will soon show the effectiveness of these new vaccines.

Grady, Denise. "2 New Ebola Vaccines Pass Important Early Test, Researchers Say." The New York Times. The New York Times, 08 Apr. 2015. Web. 20 Apr. 2015.
blog comments powered by Disqus

TuftScope: The Interdisciplinary Journal of Health, Ethics, and Policy

TuftScope is a student journal published biannually in conjunction with Tufts University since 2001. Funding is provided by the Tufts Community Union Senate. The opinions expressed on this weblog are solely those of the authors. The staff reserves the right to edit blog postings for clarity and to remove nonfunctional links.

  © Free Blogger Templates Autumn Leaves by 2008

Back to TOP